“We are actively working to scale up this collaborative post-arrival airport-based surveillance testing program to monitor for this new variant in arriving travelers.”
On Sunday, November 28, XpresCheck expanded its COVID-19 biosurveillance program to test passengers entering the United States from Southern Africa, including passengers making connections through Europe. The initial COVID-19 biosurveillance program launched in September and provided testing for travelers arriving from India at three key United States airports, John F.
Kennedy International Airport, Newark-Liberty International Airport, and San Francisco International Airport, and is expanding to include Hartsfield-Jackson Atlanta International Airport.
The CDC’s program, conducted in collaboration with XpresCheck and Ginkgo Bioworks, offers two types of free testing options. The first is a PCR test done on a pooled sample collected at the airport on arrival. A pooled test means several passengers’ samples are combined together and tested as a group. This approach enables efficient large-scale testing of many passengers entering the country. The second option is an at-home specimen collection kit that passengers can take with them and mail back a sample collected three to five days after arrival into the United States for individualized PCR testing.
The CDC strongly encourages all international travelers to get tested three to five days after arrival in the United States. Through this program, results are provided to passengers and public health authorities to help interrupt the chain of transmission in US communities, and detect variants of concern entering the United States.
News 
Market Data 
Discover 
